References
- 1. Constantinescu I. Studies on type C hepatitis epidemiology. Rev Romana Med Lab. 2005;1(1):63-6.
- 2. Perez AB, Chueca N, Garcia F. Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long? Germs. 2017 Mar;7(1):40-4. DOI: 10.18683/germs.2017.1107 10.18683/germs.2017.1107
- 3. Tacke F, Trautwein C. Mechanisms of liver fibrosis resolution. J Hepatol. 2015 Oct;63(4):1038-9. DOI: 10.1016/j.jhep.2015.03.039
- 4. Consensus Statement on HCV Infection in Romania Working Group. Consensus statement on the management of patients with HCV infection in Romania. Germs. 2017 Mar;7(1):32-9. DOI: 10.18683/germs.2017.1106 10.18683/germs.2017.1106
- 5. Dobreanu M, Enache L, Enache E. Non-invasive markers of fibrosis in chronic hepatitis C patients. Rev Romana Med Lab. 2009;14(1):7-17.
- 6. Enache E, Enache L. Versant HCV Genotype 2.0 Assay (LiPA) in Hepatitis C Virus Genotype Determination. Rev Romana Med Lab. 2008;12(3):47-53.
- 7. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005 Dec 1;192(11):1880-9. DOI: 10.1086/497701 10.1086/497701
- 8. Mangia A, Santoro R, Mottola L, Piazzolla V, Bacca D, Sarli R, et al. IL28B C/C polymorphism is predictive of spontaneous HCVRNA clearance in patients with thalassemia major. J Hepatol. 2011;52:S452. DOI: 10.1016/S0168-8278(10)61171-3
- 9. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012 Mar;19(3):173-81. DOI: 10.1111/j.1365-2893.2011.01497.x 10.1111/j.1365-2893.2011.01497.x
- 10. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul;139(1):120-9 e18.
- 11. Gheorghe L, Rugina S, Dumitru IM, Franciuc I, Martinescu A, Balas I. HLA class II alleles in Romanian patients with chronic hepatitis C. Germs. 2015 Jun;5(2):44-9. DOI: 10.11599/germs.2015.1070 10.11599/germs.2015.1070
- 12. Gheorghe L, Rugină S, Dumitru I, Franciuc I, Martinescu A, Năstase V, et al. Association of HLA-DQB1 alleles with interferon/ribavirin therapy outcomes in a Romanian patient group infected with hepatitis C virus genotype 1b. J Contemp Clin Pract. 2016;2(2):50-8. DOI: 10.18683/jccp.2016.1013
- 13. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346-55.DOI: 10.7326/0003-4819-140-5-200403020-00010 10.7326/0003-4819-140-5-200403020-00010
- 14. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4):1335-74. DOI: 10.1002/hep.22759 10.1002/hep.22759
- 15. Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol. 2017 Mar 07;23(9):1697-711. DOI: 10.3748/wjg.v23.i9.1697 10.3748/wjg.v23.i9.1697
- 16. Săndulescu O S-CA, Stoica MA, Preoțescu LL, Manolache D, Ceapraga GJ, Moțoi MM, Bradu L, Ilie A, Mircea G, Durbală I, Streinu-Cercel A. Regression of liver fibrosis following sustained virological response in patients with chronic HCV infection and cirrhosis. The 12th Edition of the Scientific Days of the National Institute of Infectious Diseases “Prof Dr Matei Balş” and the 12th National Infectious Diseases Conference, Bucharest, Romania; Bucharest: BMC Infect Dis; 2016. p. 46-7.
- 17. Perez AB, Garcia F. Resistance to direct antiviral agents for hepatitis C virus infection. Impact on clinical practice? Germs. 2016 Dec;6(4):123-4. DOI: 10.11599/germs.2016.1098 10.11599/germs.2016.1098
- 18. Streinu-Cercel A. Hepatitis C in the interferon-free era. Germs. 2013 Dec 1;3(4):114. DOI: 10.11599/germs.2013.1044 10.11599/germs.2013.1044
- 19. Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016 May 25;17(6). DOI: 10.3390/ijms17060803 10.3390/ijms17060803
- 20. Rusu E, Enache G, Jinga M, Dragut R, Nan R, Popescu H, et al. Medical nutrition therapy in non-alcoholic fatty liver disease - a review of literature. J Med Life. 2015;2015(3):258-62.
- 21. Oliveira CP, de Lima Sanches P, de Abreu-Silva EO, Marcadenti A. Nutrition and physical activity in nonalcoholic fatty liver disease. J Diabetes Res. 2016;2016:4597246. DOI: 10.1155/2016/4597246 10.1155/2016/4597246
- 22. Freidoony L, Deok Kong I. Practical approaches to the nutritional management of nonalcoholic fatty liver disease. Integr Med Res. 2014;3:192-7. DOI: 10.1016/j.imr.2014.09.00310.1016/j.imr.2014.09.003